Research
Personalized therapies for Crohn's and ulcerative colitis may follow from method that identifies harmful gut bacteria
The Brief
- An international team led by Dr. Lukas Mager (University Hospital Tübingen) and Prof. Kathy McCoy (University of Calgary) has developed an approach to identify gut bacteria that contribute to the development or worsening of chronic inflammation.
- The method is intended to support personalized therapies for Crohn's disease and ulcerative colitis.
- The available source excerpt does not report clinical trial results.
Why it matters
If harmful gut bacteria can be identified for individual patients, treatments for chronic intestinal inflammation could be targeted more precisely than current one-size-fits-all approaches.
Who’s affected
- patients with Crohn's disease or ulcerative colitis
- gastroenterologists and clinicians treating inflammatory bowel disease
- microbiome researchers
- #gut microbiome
- #crohn's disease
- #ulcerative colitis
- #inflammation
- #personalized medicine
Which gut bacteria contribute to the development or worsening of chronic inflammation? An international research team led by Dr. Lukas Mager from University Hospital Tübingen and Prof. Kathy McCoy from the University of Calgary has developed an approach to identify and…